Abstract

BackgroundInnovative strategies are needed to tackle childhood mortality in the rural tropics. Artesunate suppositories were developed to bring emergency treatment closer to severely ill children with malaria in rural areas where injectable treatment is not possible for several hours. Adding an antibacterial rectal drug would extend this strategy to treat non-malarial febrile illness as well. The objective of these studies was to assess acceptability of such a new pre-referral strategy by healthcare providers and likely uptake by the population.MethodsTwo qualitative studies were conducted between May and July 2009. Study 1 investigated the acceptability of introducing a combined antimalarial-antibacterial suppository by interviewing 27 representatives of the three administrative levels (central government, regional, local) of the health sector; Study 2 investigated treatment-seeking behaviour and acceptability of this intervention at community level by interviewing 74 mothers in 2 villages.Results and ConclusionsUp to 92% of health representatives were in favour of introducing a new pre-referral strategy to tackle both malaria and non-malaria related severe illnesses in Guinea-Bissau, provided it was endorsed by international health authorities. The main obstacles to implementation were the very limited human and financial resources. In the two villages surveyed, 44% of the mothers associated severe illness with fever only, or fever plus one additional symptom. Mothers’ judgement of severity and ensuing decisions were not specific for serious illness, indicating that initial training to recognize signs of severe disease and treatment availability for non-severe, fever-associated symptoms will be required to prevent overuse of a new intervention designed as a pre-referral treatment for severely ill children. Level C health centres were the first resort in both villages (50% and 87% of respondents respectively). This information is encouraging for the implementation of a pre-referral treatment.

Highlights

  • Innovative strategies are needed to tackle childhood mortality in the rural tropics

  • It has been estimated that Plasmodium falciparum malaria and acute respiratory infections (ARI) together account for 25% of childhood deaths worldwide

  • Administration of rectal artesunate as a pre-referral treatment was evaluated in a large randomized, placebo-controlled trial of more than 12,000 malaria patients conducted in Bangladesh, Ghana and Tanzania

Read more

Summary

Introduction

Innovative strategies are needed to tackle childhood mortality in the rural tropics. Artesunate suppositories were developed to bring emergency treatment closer to severely ill children with malaria in rural areas where injectable treatment is not possible for several hours. Adding an antibacterial rectal drug would extend this strategy to treat non-malarial febrile illness as well. The objective of these studies was to assess acceptability of such a new pre-referral strategy by healthcare providers and likely uptake by the population. Administration of rectal artesunate as a pre-referral treatment was evaluated in a large randomized, placebo-controlled trial of more than 12,000 malaria patients conducted in Bangladesh, Ghana and Tanzania. Such treatment reduced death or permanent disability in patients with severe malaria who experienced delays greater than six hours in reaching a health care facility [4]. Pre-referral treatment with a single dose of rectal artesunate has been introduced within the Integrated Management of Childhood Illnesses (IMCI) in remote areas

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call